Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...

UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

Two disabled Londoners are making the world’s first attempt to push themselves across the Alps in their wheelchairs, ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...

New research sheds light on the mechanisms of degeneration in multiple sclerosis, suggesting that mitochondrial dysfunction ...

The report provides a detailed analysis of the current spinocerebellar ataxia marketed drugs and late-stage pipeline drugs, advancements in treatment. BROOKLYN, NY, UNITED STATES, June 16, 2025 ...

Nearly three decades after the final episode of his beloved TV show aired, the Science Guy hasn’t lost his way. In fact, in ...

Ataxia is a condition caused by damage in cerebellum, a part of the brain, that leads to poor muscle control affecting movement. In an interview with HT Lifestyle, Dr Aniruddha More, consultant ...

Spinocerebellar ataxia type 1 (SCA1) is an inherited, fatal neurodegenerative disease caused by an abnormal expansion of glutamine (Q) encoding CAG repeats in the gene Ataxin-1 (ATXN1). Patients with ...

Reversible cerebellar disruption in non-human primates reveals an acute muscle torque deficit and an adaptive slowing strategy to manage limb dynamics, underscoring distinct primary, and compensatory ...

Solid Biosciences announces FDA clearance for SGT-212, targeting Friedreich’s ataxia with dual gene therapy administration routes, initiating Phase 1b trial in 2025. Quiver AI Summary Solid ...